Zeta RCC Antibody. Zeta’s monoclonal mouse antibody recognizes RCC (Renal Cell Crcinoma), a surface membrane molecule located on the brush border of proximal renal tubules and expressed on the luminal surface of Bowman capsule, parathyroid parenchymal cells and colloid of thyroid follicles. The RCC antibody detects a 200 kD glycoprotein (gp200). In normal kidney, RCC is localized along the brush border of the pars convoluta and pars recta segments of the proximal tubule, as well as focally along the luminal surface of Bowman’s capsule adjoining the outgoing proximal tubule. Of other normal tissues examined, RCC is localized along the luminal surfaces of breast lobules and ducts, the luminal surface of the epididymal tubular epithelium, within the cytoplasm of parathyroid parenchymal cells, and focally within the colloid of thyroid follicles. Thirty-one other normal tissues do not express RCC or cross-reacting antigens. RCC is expressed by 93% of primary and 84% of metastatic renal cell carcinomas. The RCC antibody may be a useful reagent in the investigations of carcinomas of proximal nephrogenic differentiation especially those showing tubular differentiation.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.